Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. Our current focus is on respiratory fungal infections, which can be serious and life-threatening and which may significantly impact a patient’s quality of life. Pulmocide’s innovative approach to drug design offers a novel investigational inhaled antifungal therapy that has been specifically designed to treat one of the most common and life-threatening fungal lung diseases, pulmonary aspergillosis.
Opelconazole, an investigational product, was designed to be a potent inhaled antifungal agent so that high concentrations of the drug could reach, and be retained at, the site of infection in the lung with minimal systemic exposure in an effort to improve patient outcomes and reduce the potential for side effects and drug interactions. Our lead Phase 3 clinical trial program is evaluating opelconazole for the treatment of patients with invasive pulmonary aspergillosis who are not responding to standard-of-care antifungal medicines. An additional clinical safety study exploring prophylaxis in lung transplant recipients is also ongoing.
Pulmocide was cofounded by Dr. Pete Strong, Dr. Garth Rapeport, Dr. Kazuhiro Ito, and Dr. John Murray. The Pulmocide team is experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications, with particular expertise in the identification of novel compounds that are suited for delivery directly to the lungs.